2025;e2520947
Structure Therapeutics reports positive topline data from phase 2 ACCESS II trial with once-daily oral small molecule GLP-1 receptor agonist, aleniglipron
Neurosci Biobehav Rev 117:253
We recommend regular skin cancer screening, moderate ordination of photosensitizing medication, but above all comprehensive clarification of possible risks
Patients prescribed a GLP-1 agent should also be encouraged to eat slowly, eat smaller meals, and if needed, adjust the timing of their GLP-1 dose in relation to food intake
Those that do not educate themselves (while losing weight) with proper nutrition, make mindset shifts, changes in daily habits, deal with emotional eating and stress will gain all their weight back, plus some